Methyl-CpG-binding protein 2 (MeCP2) is a classic methylated-DNA-binding protein, dysfunctions of which lead to various neurodevelopmental disorders such as Rett syndrome and autism spectrum disorder. Initially recognized as a transcriptional repressor, MeCP2 has been studied extensively and its functions have been expanded dramatically in the past two decades. Recently, it was found to be involved in gene regulation at the post-transcriptional level. MeCP2 represses nuclear microRNA processing by interacting directly with the Drosha/DGCR8 complex. In addition to its multifaceted functions, MeCP2 is remarkably modulated by posttranslational modifi cations such as phosphorylation, SUMOylation, and acetylation, providing more regulatory dimensions to its functions. The role of MeCP2 in the central nervous system has been studied extensively, from neurons to glia. Future investigations combining molecular, cellular, and physiological methods are necessary for defi ning the roles of MeCP2 in the brain and developing effi cient treatments for MeCP2-related brain disorders.
Introduction
Methyl-CpG-binding protein 2 (MeCP2) was initially identified in 1992 as a classic methyl-CpG-binding protein [1] . Since DNA methylation was considered to be an important epigenetic mechanism for the regulation of gene transcription [2, 3] (Fig. 1A) , MeCP2 was then regarded as a transcriptional repressor and the methyl-DNA-binding domain and transcriptional repression domain were revealed by subsequent biochemical studies [4, 5] (Fig. 1B) .
Furthermore, many proteins such as the Sin3A/HDAC and NCoR/SMRT co-repressor complexes interact with MeCP2 [6] (Fig. 1B) , confi rming its key role in transcription repression.
The role of MeCP2 in the brain was originally discovered in 1999, when Dr. Huda Y. Zoghbi and her team found that MeCP2 mutations are the genetic root of a rare neurodevelopmental disorder named Rett syndrome (RTT, MIM312750) [7] . As MECP2 is an X-linked gene, it is not surprising that Rett syndrome mainly occurs in females, as loss-of-function mutations of MECP2 would largely be lethal in males. Classic RTT patients have normal development to 6-18 months of age, and then start to undergo growth arrest and appear to have defects in motor functions such as hand skills. Furthermore, neurological abnormalities including autistic features, seizures, and mental retardation are prevalent in the progression [8] . In accord with the clinical features of RTT patients, expression pattern analysis showed that MeCP2 expression is dominant in brain tissues, emphasizing its crucial role in neural development [9] .
The MECP2 gene is composed of four exons and alternative splicing results in two protein isoforms, MeCP2E1 and MeCP2E2, with different N-termini [10, 11] . In situ hybridization in mouse brain showed that Mecp2e2 expression is restricted to the dorsal thalamus while
Mecp2e1 is the major brain isoform outside the thalamus [12] . Furthermore, expression analysis in human brain tissues revealed that the MECP2E1 mRNA level is significantly higher than MECP2E2 in the whole brain or cerebellum [11] . With the development of MeCP2 isoformspecific antibodies, researchers have investigated the expression of both isoforms at the protein level during brain development and in various brain regions, and found a later onset of MeCP2E2 expression than MeCP2E1 [13] .
We further showed that the MeCP2E2 expression patterns in different brain regions are quite different while the MeCP2E1 expression pattern is uniform [13] . Although both isoforms have been detected in many cell types including neurons, astrocytes, and oligodendrocytes, MeCP2E1
is significantly higher in neurons than in astrocytes [14] . In addition, MeCP2E1 and MeCP2E2 have quite different functions in neuronal survival [15] , embryonic development [16] and responses to drugs [17] .
RTT disorder is mainly caused by MeCP2 defi ciency, [22, 23] .
Initially, MeCP2 was thought to be present mainly in excitatory neurons [24] . However, after decades of study, transcription and a decrease of neuronal excitability [27] .
However, MeCP2 is not just a transcriptional repressor, as transcriptional profiling analysis in the hypothalamus and cerebellum of Mecp2 knockout/transgenic mice revealed a bi-directional change of gene expression [28, 29] . Consistently, protein interaction analysis has shown that MeCP2
interacts not only with co-repressor complexes [6, 30, 31] but also with the transcriptional activator CREB [28] (Fig.   1B ). So it was proposed that MeCP2 also serves as a transcriptional activator to stimulate gene expression (Fig. 2) . The transcriptional-activation function of MeCP2 has been further confi rmed in astrocytes [32] . However, the underlying mechanisms remain to be determined.
More intriguingly, the modulation of specific gene expression by MeCP2 can change dynamically between repression and activation. As noted above, BDNF expression can be repressed by MeCP2 in cultured cortical neurons. However, it has been demonstrated that MeCP2 overexpression promotes BDNF expression in cultured cortical neurons [33] . Furthermore, BDNF expression is upregulated in mecp2 transgenic mice and downregulated in mecp2 knockout mice, which suggests that MeCP2 promotes BDNF expression in vitro and in vivo [28, 33] . Several hypotheses have been proposed to explain the discrepancy between these studies. For example, it has been proposed that different MeCP2 phosphorylation status could recruit distinct factors to repress or activate BDNF expression [34] .
Of course, further experiments are needed to verify these hypotheses.
Gene Expression Regulated by MeCP2: from mRNAs to Non-coding RNAs
Early studies on the impact of MeCP2 on gene expression mainly focused on the transcriptional level. However, transcripts of protein-coding genes only account for onefi fth of all transcripts in the genome [35] . Indeed, non-coding RNAs including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are abundant in the nervous system and they are critical for neuronal functions and brain development [36, 37] . It is well-known that miRNAs modulate gene expression post-transcriptionally to infl uence various aspects of neuronal functions from cell fate determination to synaptic plasticity. For example, miR-124a and miR-9
are essential for neural lineage differentiation and are involved in determining neural progenitor differentiation into neurons or glia [38] , while miR-134 is located in synapses and is involved in spine development [39] .
lncRNAs physically interact with transcriptional factors and chromatin remodelers to modulate gene expression and regulate neuronal functions [40, 41] . For instance, the specifi c lncRNA RMST interacts with hnRNPA2/B1 and SOX2 to regulate gene transcription and finally influence neuronal differentiation [42] . As the transcriptional process is similar in protein-coding and non-coding genes, and MeCP2 is a transcriptional regulator, it is likely that the transcription of non-coding RNAs is regulated by MeCP2. As expected, deletion of Mecp2 results in disrupted expression of miRNAs and lncRNAs in the mouse model of RTT [43] [44] [45] .
These results underscore the essential role of MeCP2 in transcriptional regulation and suggest that MeCP2 might modulate genome transcription globally, independent of RNA type.
Modulation of Gene Expression at the Post-
transcriptional Level by MeCP2: miRNA Processing, RNA Splicing, and Protein Synthesis?
The involvement of MeCP2 in regulating miRNA expression was first reported in adult neural stem cells, in which miR-137 was up-regulated after MeCP2 knockdown and proliferation/differentiation balance was impaired [46] . Then, further studies analyzed the expression profi les of miRNAs in the whole brain or cerebellum of Mecp2-null mice and found that the levels of many miRNAs were altered [43, 44] .
Although studies indicate that the expression of several miRNAs is regulated by MeCP2 at the transcriptional level, recently it has been reported that MeCP2 can also regulate miRNA expression post-transcriptionally [47] . Solexa-based deep sequencing revealed that most mature miRNAs are up-regulated in the hippocampus of MeCP2-knockout mice. MeCP2 affects the RNA-splicing process and abnormal alternative splicing events have been reported in a mouse model of RTT [48] . Consistently, MeCP2 depletion in nonneuronal cell lines also impairs the process of alternative splicing [49] (Fig. 2) . Further studies using mass spectrometry have identifi ed several RNA-binding proteins and splicing factors as MeCP2 partners, providing compelling evidence that MeCP2 is a critical factor in the RNA-splicing process [50] .
It has been reported that protein synthesis is impaired and the translation rate is reduced significantly in Mecp2 mutant brains [51] . As MeCP2 is located in the nucleus and is not a ribosome-resident protein, the involvement of mTOR pathway, is reduced in Mecp2 mutant mice [51] .
Impact of Post-translational Modifications on

MeCP2 Functions
Protein functions can be modulated by post-translational modifications such as phosphorylation, acetylation, and SUMOylation. Such modifications alter protein structure and change their physical interactions with other components, leading to changes in protein localization and signal transduction in cells [52] . Various modifications of MeCP2 have been identified (Fig. 3) . Repression of BDNF expression by MeCP2 is relieved by membrane depolarization in neurons and such de-repression depends on Ca 2+ -mediated MeCP2 phosphorylation [25] . And using mass spectrometry, multiple phosphorylation sites in MeCP2 under different conditions have been identifi ed [53] .
Of these, Serine-421 (S421) has attracted much attention as its phosphorylation is triggered by physiological stimuli such as neuronal depolarization and behavioral stimuli [54, 55] . The importance of activity-dependent MeCP2 phosphorylation at S421 has been investigated extensively.
Indeed, studies in brain slices have shown that S421 phosphorylation is essential for dendritic branching and spine morphogenesis [54] . Furthermore, MeCP2 S421A mutant mice show impaired responses to novelty [56] .
Learning and memory tests have further shown that longterm potentiation in the hippocampus and hippocampusdependent memory are enhanced, while excitatory synaptogenesis is promoted in these mutant mice, implying a critical role of S421 phosphorylation in neuronal and brain circuit development [55] . Exploration of the molecular mechanisms has shown that phosphorylation at the S421 site modulates the binding of MeCP2 to the neuronal genome and in the case of BDNF, S421 phosphorylation blocks MeCP2 binding to the BDNF promoter, leading to the activation of BDNF expression under conditions of neuronal depolarization [25] . Consistently, another study showed that
MeCP2 protein with the S421A mutation has a higher binding affi nity to multiple target-gene promoters to either enhance or repress the expression of the target gene [55] .
The Serine 80 site of the MeCP2 protein can also be phosphorylated. However, MeCP2 S80 is heavily phosphorylated under normal conditions while neuronal activity leads to its dephosphorylation [53] . Functional analysis showed that phosphorylation at S80 is essential for MeCP2 binding to the promoters of specific targets, while dephosphorylation induces the dissociation of MeCP2 from gene promoters. In addition, S80 phosphorylation inhibits the intra-molecular interaction of MeCP2, resulting in enhancement of the physical interaction between MeCP2
and DGCR8, and such interaction interferes with the miRNA processing mediated by the Drosha/DGCR8 complex [47] .
Recently, researchers have found that MeCP2 represses gene transcription via interactions with
NCoR/SMRT co-repressor complexes, and MeCP2 phosphorylation is essential for such interactions [30, 31] .
Phosphotryptic mapping has identifi ed a novel site, T308, phosphorylation of which is induced by neuronal activity, and functional analysis has revealed that phosphorylation of T308 interrupts the physical interaction between MeCP2 and the NCoR complex, thus inhibiting the transcriptional suppression effect of MeCP2 [30] .
Besides phosphorylation, other post-translational complex. SUMOylation at MeCP2 K223 is important for the transcriptional-repression effect of MeCP2 and for synaptic development [58] .
In sum, phosphorylation, acetylation, and SUMOylation 
MeCP2 in Neurons: Importance for Excitatory and Inhibitory Neurons and Glia
Initially, studies on the effect of MeCP2 on neuronal functions mainly focused on excitatory neurons [24] .
Electrophysiological studies showed that long-term potentiation recorded in cortical/hippocampal slices is reduced in Mecp2-null mice [59] and enhanced in Mecp2 transgenic mice [21] . The magnitude of synaptic output in MeCP2-null and transgenic neurons showed that the amplitude/frequency of excitatory postsynaptic currents is inhibited/enhanced under MeCP2 knockout/overexpression conditions [24] . Consistent with these results, further immunohistochemical analysis revealed that glutamatergic synapse formation is indeed regulated by MeCP2.
In addition to glutamatergic neurons, MeCP2 is also critical for dopaminergic and serotoninergic neurons, as
MeCP2 deletion in either type leads to motor impairment and increased aggression, respectively [60] . Furthermore, though researchers initially thought that MeCP2 was only expressed in excitatory neurons, subsequent studies revealed that mice with MeCP2 depletion in GABAergic neurons manifest many of the phenotypes of RTT [61] . All these results confirm that MeCP2 is critical for normal functions of various neuronal types rather than being limited to excitatory neurons.
Neurons are not the only cell type in the central nervous system. In fact, the major type in brain is glia:
astrocytes, oligodendrocytes, and microglia. MeCP2 expression was initially thought to be limited to neurons.
However, subsequent studies showed that MeCP2 is expressed in both neurons and glia. Importantly, deletion of MeCP2 in astrocytes impairs neural development and functions in a non-cell-autonomous manner [62, 63] . And in support of these observations, MeCP2 re-expression solely in astrocytes in MeCP2-null mice alleviates many of the abnormal features of RTT mouse models, implying the involvement of astrocytes in the pathogenesis of RTT. Thus, targeting astrocytes is promising for the treatment of RTT patients. In addition to astrocytes, dysfunctions of two other glial types, oligodendrocytes and microglia, also contribute to RTT neuropathology [64] . Surprisingly, transplantation of wild-type bone marrow, the source of microglia, markedly arrests the progression of RTT symptoms and further investigations have shown that impaired phagocytic activity in microglia is critical for the development and progression of RTT symptoms [65] . This study also supports the idea that bone marrow transplantation is feasible for the treatment of RTT patients.
Concluding Remarks
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